Germany Takes a Major Step Toward Access to TK2d Therapy

2 Sep, 2026

A significant milestone has been reached for families affected by TK2d: Germany has now formally recognised Kygevvi®, the first disease‑specific therapy for thymidine kinase 2 deficiency, in national pharmaceutical guidance. As reported in Pharmazeutische Zeitung, “Mit Kygevvi® steht nun erstmals ein spezifisches Therapeutikum für Patienten mit genetisch bestätigter Tk2d zur Verfügung.” This marks an important step toward real‑world access for patients in Germany — and a moment of hope for the global mitochondrial community.

Kygevvi® (a combination of Doxecitin and Doxribtimin) is designed to support mitochondrial DNA maintenance, addressing the underlying biochemical defect in TK2d rather than offering only symptomatic care. It is approved for children and adults whose symptoms began before age twelve, providing a long‑awaited therapeutic option for a condition that is both progressive and life‑limiting.

For IMP members, this development is highly relevant. Germany’s recognition of Kygevvi® may help pave the way for other countries to follow, especially as clinicians, regulators and patient organisations across Europe consider pathways for equitable access. Each national approval brings us closer to a future where TK2d patients worldwide can benefit from a therapy with the potential to change the course of their disease.